

Cancer

Immunotherapy for the Treatment of Skin Cancers

Brendan D. Curti, MD

Robert W. Franz Chair for Clinical Research

Earle A. Chiles Research Institute at Providence Cancer Institute

#LearnACI









Society for Immunotherapy of Cancer






- Consulting Fees: Merck, Clinigen, Nektar
- Contracted Research: Galectin Therapeutics, Clinigen, BMS (Institution), AZ (Institution)
- I am neither employed nor have equity interests in any company or entity whose products/drugs will be discussed today.
- I will be discussing non-FDA approved indications during my presentation.





Background

- Skin cancer is the most common type of cancer
- Three most common types of skin cancers:
 - Basal cell carcinoma
 - Squamous cell carcinoma
 - Melanoma
- Melanoma was one of the tumor types for which immunotherapy was tested and provided proof of concept









- Melanoma
 - Front-line treatment
 - Second-line or later
 - Adjuvant and neoadjuvant settings
- Merkel cell carcinoma
- Squamous cell and basal cell carcinoma
- Future areas of research





Immunotherapy treatment options for metastatic melanoma

Treatment	Indication	Dose
Ipilimumab	Unresectable/Metastatic melanoma: newly diagnosed or after progression, all patients ≥ 12 yr	3 mg/kg Q3W for 4 doses
Pembrolizumab	Unresectable/metastatic melanoma	200 mg Q3W or 400 mg Q6W
Nivolumab	Unresectable/metastatic melanoma	240 mg Q2W or 480 mg Q4W
Nivolumab + ipilimumab	Unresectable/metastatic melanoma	1 mg/kg nivo followed by 3 mg/kg ipi Q3W, Maintenance: nivolumab 240 mg Q2W or 480 mg Q4W
Atezolizumab + cobimetinib + vemurafenib	BRAF V600 mutation-positive unresectable/metastatic melanoma	28-day cycle of cobi/vem, then atezolizumab 840 mg every 2 weeks with cobimetinib 60 mg orally once daily (21 days on/7 days off) and vemurafenib 720 mg orally twice daily
Talimogene laherparepvec (T-Vec)	Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in recurrent melanoma after surgery	Intralesional injection: ≤4 mL at 10 ⁶ PFU/mL starting; 10 ⁸ PFU/mL subsequent



#LearnACI



Trials leading to initial approvals

Trial	Treatment arms	n	Patient selection criteria	ORR	Median OS (months)	Median PFS (months)
	Ipilimumab + gp100	403	Pretreated	5.7%	10.0	2.76
NCT00094653	Ipilimumab	137	advanced melanoma	10.9%	10.1	2.86
	Gp100	136	melanoma	1.5%	6.4	2.76
	Pembrolizumab	368	Advanced	33.7%, 32.9%	32.7	8.4
KEYNOTE-006	Ipilimumab	181	melanoma, ≤1 prior treatment	11.9%	15.9	3.4
	Nivolumab	272	Melanoma with	27%	16	3.1
CheckMate 037	Chemotherapy	133	progression on ipilimumab	10%	14	3.7
OPTiM	T-VEC	295	Unresectable stage IIIB-IV	26.4%	23.3	TTF: 8.2
OFTIN	GM-CSF	141	melanoma	5.7%	18.9	TTF: 2.9

Robert, N Engl J Med 2015; Robert, Lancet 2019; Hodi, N Engl J Med 2010; Larkin, J Clin Oncol 2018.

© 2020–2021 Society for Immunotherapy of Cancer









Trials in front-line melanoma

Trial	Treatment arm(s)	N	Patient selection criteria	ORR	Median PFS (months)	Landmark OS rate	Grade 3+ adverse events (%)
KEYNOTE-001	Pembrolizumab	655	Front-line	52%	16.9	5-year: 41%	17%
KETNOTE-001	Fembronzumab	033	ITT	41%	8.3	5-year: 34%	1770
	Nivolumab + ipilimumab	314	Untreated stage III or IV	58%	11.5	5-year: 52%	59%
CheckMate 067	Nivolumab	316	melanoma	45%	6.9	5-year: 44%	23%
	Ipilimumab	315		19%	2.9	5-year: 26%	28%
	Nivolumab	210	Untreated BRAF WT	42.9%	5.1	3-year: 51.2%	15%
CheckMate 066	Dacarbazine	208	advanced melanoma	14.4%	2.2	3-year: 21.6%	17.6%
IMspire150	Atezolizumab + cobimetinib + vemurafenib	256	BRAF V600 mutation- positive advanced/	66.3%	15.1	2-year: 60%	79%
	Cobimetinib + vemurafenib	258	metastatic melanoma	65.0%	10.6	2-year: 53%	73%

sitc

Society for Immunotherapy of Cancer




- Consider combination ipilimumab/nivolumab up-front for patients with:
 - Brain metastases
 - Mucosal melanoma
 - High disease burden






- Consider combination ipilimumab/nivolumab up-front for patients with:
 - Brain metastases
 - Mucosal melanoma
 - High disease burden






- Consider combination ipilimumab/nivolumab up-front for patients with:
 - Brain metastases
 - Mucosal melanoma
 - High disease burden



-ACCC



- Consider combination ipilimumab/nivolumab up-front for patients with:
 - Brain metastases
 - Mucosal melanoma
 - High disease burden









Question: Does the sequence of targeted therapy and immunotherapy impact response?

Retrospective data suggests that patients who received BRAF inhibitors <u>prior</u> to treatment with pembrolizumab tended to have poorer outcomes on pembrolizumab therapy than those patients without prior BRAF inhibitor exposure.







#LearnACI



Adjuvant treatment options for melanoma

Drug	Indication	Dose
Dabrafenib + trametinib ⁺	Adjuvant BRAF+ melanoma with lymph node involvement following complete resection	Dabrafenib 150 mg twice daily + trametinib 2 mg daily
High-dose interferon alfa-2b*	Adjuvant – high risk for systemic recurrence	Induction: 20m IU/m ² IV 5x/wk for 4 wks Maintenance: 10m IU/m ² s.c. 3x/wk for 48 wks
Ipilimumab*	Adjuvant therapy in stage III melanoma after complete resection	10 mg/kg Q3W for 4 doses, then 10 mg/kg Q12W for 3 years
Pembrolizumab	Adjuvant therapy of melanoma following complete resection – 1 year	200 mg Q3W or 400 mg Q6W
Nivolumab	Adjuvant treatment of melanoma after complete resection – 1 year	240 mg Q2W or 480 mg Q4W

*Not an immunotherapy; for reference

*not commonly used in this setting; historical reference



#LearnACI



Trials of adjuvant immunotherapy


Trial	Arms	Patient population	Ν	Key outcomes
EORTC 18071	Ipilimumab	Completely resected stage III	475	RFS HR: 0.76
EORIC 10071	Placebo	melanoma	476	OS HR: 0.72
EORTC 1325-	Pembrolizumab	High risk resected stage III	514	RFS HR: 0.56
MG/KEYNOTE-054	Placebo	melanoma	505	KF3 HK. 0.30
CheckMate 238	Nivolumab	Resected stage IIIb or IV	453	RFS HR: 0.66
Checkiviate 258	Ipilimumab	melanoma	453	KFS HK. 0.00
	Ipilimumab 3 mg/kg		523	RFS HR: 0.85 OS HR: 0.78
E1609	Ipilimumab 10 mg/kg	Resected stage IIIb-M1b melanoma	511	RFS HR: 0.84 OS HR: 0.88
	High-dose interferon alfa		636	





Adjuvant treatment considerations

- Goals of adjuvant treatment are different than goals of primary treatment
- Toxicity and quality of life are important considerations



Treatment-related adverse events





In development: Neoadjuvant immunotherapy in advanced melanoma

Trial	Regimen	Ν	pCR (%)	Median RFS (months)	Median follow-up (months)
Amaria Lancet Oncol 2018 (reference non-IO trial)	Dabrafenib + trametinib	21	58	19.7	18.6
Long Lancet Oncol 2019 (reference non-IO trial)	Dabrafenib + trametinib	35	49	23.0	27.0
Blank Nat Med 2018	Ipilimumab + nivolumab	10	33	NR	32
	Nivolumab	12	25	NR	
Amaria Nat Med 2018	Ipilimumab + nivolumab	11	45	NR	20
Huang Nat Med 2019	Pembrolizumab	30	19	NR	18
Rozeman Lancet Oncol 2019	Ipilimumab + nivolumab	86	57	NR	8.3

© 2020–2021 Society for Immunotherapy of Cancer

#LearnACI








- Melanoma
 - Front-line treatment
 - Second-line or later
 - Adjuvant and neoadjuvant settings
- Merkel cell carcinoma
- Squamous cell and basal cell carcinoma
- Future areas of research





Merkel cell carcinoma

- Associated with Merkel cell polyomavirus infection
- Higher incidence with weakened immune system (HIV, immunosuppressives) and increased age
- Distinct genomic profiles for UV- and virus-driven carcinomas
- Median PFS with chemo: ~90 days







Approved checkpoint inhibitors in Merkel cell carcinoma

Drug	Indication	Dose
Avelumab*	Patients >12 yr with metastatic Merkel cell carcinoma	800 mg Q2W + premedication (first 4 cycles)
Pembrolizumab	Adult/pediatric with recurrent advanced/metastatic Merkel cell carcinoma	Adults: 200 mg Q3W or 400 mg Q6W Pediatric: 2 mg/kg (up to 200 mg) Q3W

*Requires premedication with an antihistamine and acetaminophen prior to first four infusions







Avelumab in Merkel cell carcinoma

Setting	N	ORR	Median PFS	Median OS
First line	39	62.1%	9.1 months	
Second+ line	88	33.0%		12.6 months

First line




D'Angelo, JAMA Oncol 2018. D'Angelo, J Immunother Cancer 2020. © 2020–2021 Society for Immunotherapy of Cancer



Second+ line



Pembrolizumab in 1st-line advanced Merkel cell carcinoma



Also an ongoing trial of adjuvant pembrolizumab for Merkel cell carcinoma (NCT03712605).










- Melanoma
 - Front-line treatment
 - Second-line or later
 - Adjuvant and neoadjuvant settings
- Merkel cell carcinoma
- Squamous cell and basal cell carcinoma
- Future areas of research






Cutaneous squamous cell carcinoma

- Second-most common skin cancer
- Associated with high TMB and immunotherapy responsiveness







Approved checkpoint inhibitors for cutaneous squamous cell carcinoma

Drug	Indication	Dose
Cemiplimab-rwlc	Metastatic cutaneous squamous cell carcinoma, not candidate for curative therapies	350 mg Q3W
Pembrolizumab	Metastatic cutaneous squamous cell carcinoma	200 mg Q3W or 400 mg Q6W







Trials for R/M cutaneous SCC

Trial	Treatment	Ν	ORR	Median OS	Median PFS
KEYNOTE-629	Pembrolizumab	105	34.3%	NR	6.9 months
NCT02760498	Cemiplimab	59	47%	NR	NR





Pembrolizumab



sitc

Society for Immunotherapy of Cancer



Approved checkpoint inhibitor for basal cell carcinoma

Drug	Indication	Dose
Cominlimah	Locally advanced BCC previously treated with hedgehog pathway inhibitor or for whom HHI is not appropriate	250 mg O 2W/
Cemiplimab	Metastatic BCC previously treated with hedgehog pathway inhibitor or for whom HHI is not appropriate*	350 mg Q3W
	*Accelerated approval	

Locally advanced disease	Metastatic disease
ORR: 29%	ORR: 21%
CR: 5/84	PR: 6/28
PR: 19/84	












- Melanoma
 - Front-line treatment
 - Second-line or later
 - Adjuvant and neoadjuvant settings
- Merkel cell carcinoma
- Squamous cell carcinoma
- Future areas of research






In development: Combination IO with BRAF targeted therapy



Multiple other triplet regimens are being tested.




© 2020–2021 Society for Immunotherapy of Cancer

#LearnACI





In development: Combination IO with oncolytic virus








In development: Combination IO with pegylated IL-2 (NKTR-214)

Efficacy (response rate) data from nonrandomized cohorts of urothelial bladder cancer, renal cell carcinoma, and melanoma looks promising Stage IV IO-Naïve 1L Melanoma Cohort at RP2D Best Overall Response by Independent Radiology



1L Melanoma (n=38 Efficacy Evaluable)	Overall Response Rate
Confirmed ORR (CR+PR)	20 (53%)
CR	9 (24%)
DCR (CR+PR+SD)	29 (76%)
PD-L1 negative (n=14)	6 (43%)
PD-L1 positive (n=19)	13 (68%)
PD-L1 unknown (n=5)	1 (20%)
LDH > ULN (n=11)	5 (45%)
Liver metastases (n=10)	5 (50%)

High level of concordance in ORR between independent central radiology (53%) and investigator-assessed 19/38 (50%).





Other Selected Melanoma Research Areas:

- Tebentafusp (bispecific antibody targeting gp100 and CD3) in uveal melanomas
- Tumor infiltrating lymphocytes (TIL) after progression on T-cell checkpoint therapies
- Agents that modulate the tumor microenvironment + checkpoints
 - GR-MD-02 (belapectin) + pembrolizumab
 - STING agonists
 - Beta-catenin inhibition
 - (many others)





Conclusions


- Melanoma was one of the foundational disease states for testing immunotherapies
- Avelumab and pembrolizumab are now approved for Merkel cell carcinoma, and cemiplimab and pembrolizumab are approved for cutaneous squamous cell carcinoma
- Combination immunotherapies may lead to higher response rates and more durable responses





Additional Resources









Case Studies








- 50 year old woman who presented with a changing pigmented lesion of the left temple in 2013. Biopsy showed a 0.91 mm melanoma without ulceration and < 1 mitosis/mm². SLN was negative. The initial pathological stage was pT1apN0M0 (Stage 1A).
- She developed RUQ pain in May 2017. She reported to the ER and CT

showed:



There were multiple pulmonary, lymph node and soft tissue nodules. Biopsy confirmed melanoma and a BRAF V600E mutation was present. There was no PD-L1 expression detected.





What is the best treatment option?


- A. Ipilimumab + nivolumab
- B. BRAF-targeted therapy (e.g.: vemurafenib or dabrafenib)
- C. TVEC
- D. BRAF + MEK targeted therapy (e.g.: dabrafenib + trametinib)
- E. Clinical trial





Case 1 continued:

- The patient volunteered for the E6134 study (DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing), A Phase III Study) and was randomized to ipilimumab + nivolumab.
- Restaging imaging showed:





Complete response of all target lesions, lasting ~ 36 months after diagnosis. . .








Case 1 continued:

- Ipilimumab + Nivolumab was administered x 3 cycles only
- Immune-mediated adverse events included:
 - Grade 3 diarrhea
 - Grade 3 transaminitis (ALT max ~300)
 - Grade 3 hypothyroidism (TSH ~80)
- High dose oral steroids with a slow taper and levothyroxine (ongoing) have addressed the irAEs.





Case I continued:




36 months after ipilimumab and nivolumab, a new solitary left adrenal metastasis appears. Treatment options include SBRT or initiation of BRAF-targeted therapy.



© 2020–2021 Society for Immunotherapy of Cancer



Case I continued:



2 months after SBRT, the adrenal nodule is regressing, but a new SQ nodule appears.



© 2020–2021 Society for Immunotherapy of Cancer




Case 2





- 72 year old man who presented with a changing lesion on the scalp vertex. Biopsy reveals a BRAF wild type melanoma with a Breslow depth of 1.7mm, ulceration and 14 mitoses per mm². Initial therapy is WLE and SLN procedure; 1 out of 6 LNs contain melanoma. Initial stage is pT2bpN1aM0 stage IIIB.
- After surgery:
 - Adjuvant nivolumab x 1 year. Developed grade IV lichenoid mucositis requiring steroids and mycophenolate mofetil.
 - Melanoma-free for ~10 months and then develops new scalp and neck nodules:







What treatment option would you recommend?


- A. Another trial of T-cell checkpoint therapy (e.g.: Ipi/Nivo)
- B. Talimogene laherparepvec (TVEC)
- C. Clinical trial
- D. High dose IL-2





Case 2 continued:

- He opts for TVEC, which was well tolerated.
- Best response to TVEC was PD in < 3 months with ~30 new SQ, intramuscular and LN sites.






Case 2 continued:

- Treatment options considered were:
 - Resumption of T-cell checkpoint antibody therapy
 - Clinical trial
 - High-dose IL-2
- The patient opts for high-dose IL-2
- He experiences anticipated toxicities including hypotension, acute kidney injury, metabolic acidosis, thrombocytopenia and hypoglycemia (hypothesized due to T cell metabolism from IL-2)
- Residual lichen planus from prior checkpoint immunotherapy gradually resolved during IL-2.





Case 2: Complete Response after IL-2 (occurring after checkpoint and TVEC progression)



© 2020–2021 Society for Immunotherapy of Cancer